Artoss Prospective Spine Registry Outcomes

About this trial

Last updated a year ago

Study ID

SF-100

Status

Active not recruiting

Type

Observational

Placebo

Accepting

18+ Years

All Sexes

Trial Timing

Ended a year ago

What is this trial about?

This prospective registry was designed as an observational study to ascertain how commercially available NanoBone Bone Graft is being used by surgeons performing spinal fusion as well as determining relevant patient outcomes.

What are the participation requirements?

Inclusion Criteria

* Patient aged 18 years or older * Patient is diagnosed with a degenerative spine disorder requiring spinal fusion, has failed conservative treatment, and has decided to undergo surgery. * The surgeon has determined that a NanoBone product is or was clinically indicated, and will use or have used the product as a stand-alone bone graft substitute or in combination with local autograft only (no iliac crest harvesting, other BGS, or biologic {defined as containing growth factors, cytokines, proteins, or cells} used). * Patient capable of understanding the content of the Informed Consent Form * Patient willing and able to participate in the registry protocol including SOC follow-up visits and clinical evaluations. * Patient who has agreed to participate in the registry by providing consent according to the applicable local law and the Declaration of Helsinki. Exclusion Criteria:• Severe vascular or neurological disease * Uncontrolled diabetes * Severe degenerative disease (other than degenerative disc disease) * Severely impaired renal function * Hypercalcemia, abnormal calcium metabolism * Existing acute or chronic infections, especially at the site of the operation * Inflammatory bone disease such as osteomyelitis * Malignant tumors * Patients who are or plan to become pregnant. * Uncooperative patients who cannot or will not follow post-operative instruction, including individuals who abuse drugs and/or alcohol.

Exclusion Criteria